• Researcher Profile

    Meredith Regan, ScD

     
    Meredith Regan, ScD
     
    Associate Professor of Medicine

    Office phone: 617-632-2471
    Fax: 617-632-5444
    Email: meredith_regan@dfci.harvard.edu

    Preferred contact method: email
     
     

    Research Department

    Biostatistics and Computational Biology

    Area of Research

    Statistical Methods in Cancer Research.


    Dana-Farber Cancer Institute
    450 Brookline Avenue
    CLSB 11046
    Boston, MA 02215

    Biography

    Dr. Regan is Associate Professor of Medicine, Harvard Medical School. She earned her doctorate in Biostatistics from Harvard School of Public Health. After completing a fellowship at the Biometrics Center at Beth Israel Deaconess Medical Center, she joined the faculty at BIDMC, and in 2003 joined the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology. Dr. Regan was appointed Group Statistician for the International Breast Cancer Study Group (IBCSG) in 2009.

    Research

    Statistical Methods in Cancer Research.

    Dr. Regan’s research focuses on clinical and translational research in breast and genitourinary cancers. She is Director of the Biostatistics and Computational Biology Core of the DF/HCC Prostate Cancer SPORE, co-investigator for the Harvard/Michigan/Cornell Clinical Validation Center Early Detection Research Network (EDRN), and Data Coordinating Center Director for the PROST-QA Consortium, a multicenter longitudinal cohort study assessing health-related quality of life among men undergoing primary local therapy for prostate cancer. In a new initiative led by Dr. Christopher Sweeney, the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) Working Group is conducting an individual patient data meta-analysis to evaluate surrogate endpoints for overall survival in randomized clinical trials for localized prostate cancer treatment. 

    Dr. Regan is Group Statistician for the International Breast Cancer Study Group (IBCSG). She is the lead statistician for the international randomized clinical trials SOFT and TEXT evaluating the adjuvant endocrine therapy in premenopausal women with early-stage breast cancer. With IBCSG colleagues, her translational research focuses on features of the disease or patient that inform selection of endocrine therapy for individual patients.

    Dr. Regan’s statistical research focuses on long-term analysis of randomized clinical trials with selective crossover, in which patients on the control arm are provided the opportunity to take the experimental treatment after first dissemination of the trial’s results; the work is motivated by the international BIG 1-98 and HERA trials adjuvant early breast cancer trials.

    Select Publications

    • Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thrlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD for the SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: Who receives chemotherapy? Ann Oncol 2008;19:1231-41.
    • Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC. Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Prudkin L, Regan M, Salter J, Sotririou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011;103:1656-64.
    • Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Lang I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011;29:1117-24.
    • Pomerantz M, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozzellio G, Nakabayashi M, Oh W, Kantoff PW, Freedman ML. Association of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila) 2011;4:719-28.
    • Alemozaffar* M, Regan* MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR**, Sanda MG**. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306:1205-14.
    • Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thurlimann B, for the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 2011;12:1101-8.
    • Regan* MM, Leyland-Jones* B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell’Orto P, Biasi MO, Thürlimann V, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G, on behalf of the Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J Natl Cancer Inst 2012;104:441-51.
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now